Shore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research report released on Friday morning, ThisIsMoney.Co.Uk reports.
Other equities research analysts also recently issued reports about the stock. Deutsche Bank reissued a buy rating and issued a GBX 8,300 ($108.45) price objective on shares of AstraZeneca in a research report on Thursday. Citigroup reissued a buy rating on shares of AstraZeneca in a research report on Thursday. Jefferies Financial Group increased their price objective on shares of AstraZeneca from GBX 6,550 ($85.59) to GBX 6,700 ($87.55) and gave the company a hold rating in a research report on Tuesday, October 15th. HSBC set a GBX 6,235 ($81.47) price objective on shares of AstraZeneca and gave the company a sell rating in a research report on Thursday, October 17th. Finally, Liberum Capital raised shares of AstraZeneca from a hold rating to a buy rating and set a GBX 8,250 ($107.80) price objective on the stock in a research report on Friday, October 25th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company. AstraZeneca has a consensus rating of Hold and an average price target of GBX 7,465.67 ($97.55).
Shares of LON:AZN traded down GBX 10 ($0.13) during trading hours on Friday, reaching GBX 7,277 ($95.09). The stock had a trading volume of 1,564,493 shares, compared to its average volume of 2,310,000. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 8,227.88 ($107.51). The firm’s 50 day moving average is GBX 7,153.54 and its 200-day moving average is GBX 6,640.56. The company has a debt-to-equity ratio of 148.59, a quick ratio of 0.70 and a current ratio of 0.92. The stock has a market capitalization of $95.47 billion and a price-to-earnings ratio of 45.65.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Different Options Trading Strategies
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.